Since November 2015, when the LEADERS FREE was published in NEJM, polymer-free drug coated stents had undoubtedly been the best treatment for patients at high risk of bleeding. The benefit was owed to the safety and efficacy of the polymer-free biolimus coated stent (also called umirolimus) vs. bare metal stents in the context of just<a href="https://solaci.org/en/2020/02/27/onyx-one-more-options-for-patients-at-high-risk-for-bleeding/" title="Read more" >...</a>
New European Guidelines on the Management of Lower Limb Acute Ischemia
Clinical practice guidelines are usually tedious and, frankly, while a lot of people make an enormous effort to write them, they are ultimately read in full by just a few. These new European Guidelines on the Management of Lower Limb Acute Ischemia represent a special team effort, since they include physicians, cardiologists, surgeons, and interventionists,<a href="https://solaci.org/en/2020/02/07/new-european-guidelines-on-the-management-of-lower-limb-acute-ischemia/" title="Read more" >...</a>
Ticagrelor Monotherapy One Month After DES Implantation
The GLOBAL LEADERS study includes a pre-specified sub-study, GLASSY, that showed that ticagrelor monotherapy after one month of dual antiplatelet therapy is non-inferior (but not superior) to conventional treatment in terms of ischemic events. As regards safety, ticagrelor monotherapy did not decrease major bleeding compared with conventional therapy. The GLOBAL LEADERS randomized 15,991 patients who required<a href="https://solaci.org/en/2020/01/13/ticagrelor-monotherapy-one-month-after-des-implantation/" title="Read more" >...</a>
AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome
This study findings confirm less bleeding at no extra cost of thrombotic events when aspirin is discontinued after an acute coronary syndrome (ACS). In the same line as the original TWILIGHT, this study focused on ACS patients alone (excluding STEMI) and confirmed that aspirin discontinuation after 3-month DAPT to continue with ticagrelor alone, reduced the<a href="https://solaci.org/en/2019/11/20/aha-2019-twilight-discontinue-aspirin-after-acute-coronary-syndrome/" title="Read more" >...</a>
AHA 2019 | RECOVERY: Early Surgery in Asymptomatic Severe Aortic Stenosis
This small randomized study heated the debate about when to intervene aortic stenosis (AS). Putting off surgical valve replacement (SAVR) in patients with asymptomatic AS and waiting for symptom onset with conservative care increased periprocedural risk and all cause cardiovascular death. This study presented by Dr Duk-Hyun Kang during AHA 2019 scientific sessions (simultaneously published<a href="https://solaci.org/en/2019/11/20/aha-2019-recovery-early-surgery-in-asymptomatic-severe-aortic-stenosis/" title="Read more" >...</a>
See the 2019 Panama Sessions presentations
The XXXIX Regional SOLACI Sessions in Panama were an extremely successful scientific event. Renowned specialists in hemodynamics from all over Latin America presented their works and shared their knowledge in an event characterized by the utmost respect and comradeship. That is the reason why we share below those presentations, thanking these professionals for their contribution to our<a href="https://solaci.org/en/2019/10/21/see-the-2019-panama-sessions-presentations/" title="Read more" >...</a>
The Era of Provisional Stenting for Bifurcations Comes to an End
After the large studies which set provisional stenting as the preferred strategy to treat bifurcations comes the double kissing crush technique (DK crush) to break the mold once again. This time, the DK crush technique is tested against provisional stenting in the left main, with a 3-year follow-up. The DKCRUSH-V, soon to be published in<a href="https://solaci.org/en/2019/10/17/the-era-of-provisional-stenting-for-bifurcations-comes-to-an-end/" title="Read more" >...</a>
TCT 2019 | MODEL U-SES: More Devices for High Risk of Bleeding and Short DAPT
Courtesy of SBHCI. This study tested the safety of dual antiplatelet therapy (DAPT) after only three months of bioresorbable polymer sirolimus DES implantation (Ultimaster). Secondary end point was following with P2Y12 inhibitor monotherapy after the first 3 months compared with aspirin. It included 1695 patients treated with sirolimus eluting Ultimaster receiving 3-month DAPT. After the<a href="https://solaci.org/en/2019/09/30/tct-2019-model-u-ses-more-devices-for-high-risk-of-bleeding-and-short-dapt/" title="Read more" >...</a>
TCT 2019 | EVOLVE Short DAPT: Only 3-month DATP in High Risk Bleeding
Courtesy of the SBHCI. This study used the thin strut everolimus eluting stent with ultrathin abluminal bioresorbable polymer coating chromium platinum stent, basically the Synergy stent. Drug release and polymer degradation within four months facilitate endothelization and would allow a shorter DAPT. Presented during the scientific sessions of TCT 2019, this study included 2009 high<a href="https://solaci.org/en/2019/09/30/tct-2019-evolve-short-dapt-only-3-month-datp-in-high-risk-bleeding/" title="Read more" >...</a>
TCT 2019 | IDEAL-LM: Bioabsorbable Polymer DES vs. Permanent Polymer DES for Left Main Stenosis
Courtesy of SBHCI. This study showed that using the everolimus eluting stent with bioabsorbable polymer Synergy followed by 4 months of dual antiplatelet therapy (DAPT) to treat left main stenosis (LMS) was safe and effective, compared against using the everolimus eluting stent with permanent polymer Xience followed by the conventional 12 months DAPT. This study<a href="https://solaci.org/en/2019/09/30/tct-2019-ideal-lm-bioabsorbable-polymer-des-vs-permanent-polymer-des-for-left-main-stenosis/" title="Read more" >...</a>